Ixekizumab Diabetes Intervention Trial (I-DIT) (I-DIT)

The Effect of Anti-IL17 in New-onset Type 1 Diabetes: a Randomized, Double-blind, Placebo-controlled Trial

Although the clinical onset of type 1 diabetes (T1D) is acute, the progression of T1D occurs over many years often in a patchy manner with inflammation in certain lobes of the pancreas, leaving other lobes unaffected and long-lasting beta cells remain functional decades after diagnosis. Psoriasis share several aspects with T1D, e.g. the patchy inflammatory infiltrate consisting of tissue-resident memory (TRM) T cells, leaky blood vessels that facilitate leukocyte migration and the increased risk for systemic conditions. Moreover, interleukin (IL)-17 has shown to be increased in both persons with psoriasis and T1D. Activation of IL-17/IL-22 pathway is viewed to be both a hallmark of psoriasis and human T1D. Ixekizumab, an anti-IL17 biological agent, has shown marked therapeutic value in the treatment of subjects with psoriasis in several randomized trials and is currently an approved clinical therapy. Due to the many similarities in the current view of pathogenesis and manifestation of T1D and psoriasis it is possible that Ixekizumab can also influence the disease process of T1D.

Study Overview

• Status: Active, not recruiting
• Conditions: Type1 Diabetes Mellitus
• Intervention / Treatment: Drug: Ixekizumab; Drug: Placebo

Detailed Description

In this double-blind, placebo-controlled prospective trial, patients with newly diagnosed T1D will be randomized to receive either Ixekizumab or placebo in addition to their conventional therapy. The primary aim is to examine the effect of Ixekizumab on endogenous insulin production when administered to persons with newly diagnosed T1D. The planned study duration is 52 weeks with an extension phase for 3 years and includes 127 patients at 17 centers in Sweden. During the extension phase the participants will be examined during a visit after 1 and 3 years after the end of the study regarding insulin production (C-peptide and proinsulin secretion during a Mixed Meal Tolerance Test), glycaemic control, T1D auto-antibodies and insulin doses.

• Study Type: Interventional
• Enrollment (Estimated): 127
• Phase: Phase 2

Contacts and Locations

Study Locations

• Sweden
  • Borås, Sweden
    • Södra Älvsborg Hospital
  • Falun, Sweden
    • Falu Lasarett
  • Gothenburg, Sweden
    • Sahlgrenska University Hospital, Sahlgrenska
  • Gothenburg, Sweden
    • Sahlgrenska University Hospital, Östra Hospital
  • Jönköping, Sweden
    • Länssjukhuset Ryhov
  • Karlstad, Sweden
    • Karlstad lasarett
  • Kristianstad, Sweden
    • Kristianstad Hospital
  • Linköping, Sweden
    • Linköping University Hospital
  • Lund, Sweden
    • Lund University Hospital
  • Norrköping, Sweden
    • Vrinnevi Hospital
  • Skövde, Sweden
    • Skaraborgs Sjukhus
  • Stockholm, Sweden
    • Södersjukhuset Hospital
  • Stockholm, Sweden
    • Centrum för Diabetes,
  • Uddevalla, Sweden
    • NU-Hospital Group
  • Uppsala, Sweden
    • Uppsala Academic Hospital
  • Varberg, Sweden
    • Varbergs sjukhus
  • Örebro, Sweden
    • Orebro University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: No

Description

INCLUSION CRITERIA:

• Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations before trial activities are begun.
• Must be willing and capable of taking the study drugs and meet for tests and follow up as described.
• Diagnosed Type 1 Diabetes (E10.9) within 100 days.
• First injection of insulin maximum 100 days prior to screening
• Aged 18-45 years old.
• Presence of antibodies at clinical practice or at screening to at least one of the following antigens: insulin/IAA, GAD-65, IA-2 and ZnT8.
• Remaining stimulated peak C-peptide ≥ 0.20 nmol/L. If age 36-45 years, peak C-peptide should be <2.0 nmol/L.
• Male subjects agree to use a reliable method of birth control during the study
• Female subjects:

Participants of childbearing age or childbearing potential who are sexually active who test negative for pregnancy must be counseled and agree to use either 1 highly effective method of contraception or 2 acceptable methods of contraception combined for the duration of the study and for at least 12 weeks following the last dose of study drug or remain abstinent during the study and for at least 12 weeks following the last dose of study drug.

If the highly effective contraceptive methods are contraindicated or strictly declined by patient, acceptable birth control methods may be considered. These may include combination of both of the following methods:

• Male or female condom with spermicide

• Cap, diaphragm, or sponge with spermicide

  1. Highly effective methods of contraception (use 1 form):

     1. combined oral contraceptive pill and mini-pill
     2. NuvaRing®
     3. implantable contraceptives
     4. injectable contraceptives (such as Depo-Provera®)
     5. intrauterine device (such as Mirena® and ParaGard®)
     6. contraceptive patch-ONLY women <198 pounds or 90 kg
     7. abstinence from sex
     8. vasectomy-for men in clinical studies
  2. Effective methods of contraception (use 2 forms combined)
• male condom with spermicide
• female condom with spermicide
• diaphragm with spermicide
• cervical sponge
• cervical cap with spermicide

Females who are not of childbearing potential include those who have undergone or who have:

• female sterilization
• hysterectomy
• menopause
• Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome [also referred to as congenital absence of the uterus and vagina])

EXCLUSION CRITERIA:

• Contraindications to Ixekizumab.
• Treatment with any oral or injected glucose-lowering agents other than insulin.
• A history of haemolytic anaemia or significantly abnormal haematology/coagulation results at screening.
• Participation in other clinical trials with a new chemical entity within the previous 3 months.
• Subjects with severe obesity (BMI >35 kg/m2 if age 18-35 years and BMI >30 kg/m2 if age 36-45).
• Subjects with other autoimmune disease, e.g. Mb Crohn, Ulcerative colitis, Graves disease, psoriasis, psoriasis arthritis and axial spondylarthrosis, except celiac disease and hypothyroidism which do not need to be excluded for.
• Active serious or chronic infections (ie: in case patient had a serious infection (eg pneumonia, cellulitis), has been hospitalized, has received intravenous antibiotics for an infection within 12 weeks prior to screening visit, had a serious bone or joint infection within 24 weeks before screening visit, has ever had an infection of an artificial joint
• Known immunodeficiency or patient is immunocompromised to an extent that participation in the study would pose and unacceptable risk to the patient
• Tuberculosis
• History of HIV, hepatitis B or C
• Active or recurrent fungal infection
• Subjects with myocardial infarction, stroke, unstable angina or heart failure last 6 months
• Current clinically significant cardiac arrhythmias as verified by ECG
• Planned surgery during the treatment period of the study (except minor surgery on skin lesions, e.g., nevus)
• For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 3- months after discontinuation.
• For male subjects: intent to procreate during the duration of the study or within 3 months after discontinuation or unwillingness of their partner to use effective contraceptive measures for the duration of the study and 4 months after discontinuation.
• Any history of malignancy the last 5 years except for completely resected squamous or basal cell carcinoma of the skin.
• Administration of live attenuated vaccine(s) (LAV) within 2 months of enrolment. Or intended use of LAV during the treatment period.
• The investigator judges that the clinical diagnosis of T1D set is incorrect or uncertain (needs to be confirmed by discussion with experienced diabetologist if excluding due to this criterion)
• Allergy against ingredients of the investigational products.
• Known allergy or hypersensitivity to any biologic therapy (active substance or excipients) that would pose an unacceptable risk to the patient if participating in the study
• Presence of serious disease or condition, which in the opinion of the investigator makes the patient non-eligible for the study.
• Liver injury criteria: patients with active hepatobiliary diseases or at screening having alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal (>2.5 x ULN)

• Laboratory abnormalities at screening:

  1. Neutrophil count < 1,500 cells/ μL (=1,5 *109 cells/ L)
  2. Platelet count < 100,000 cells/ μL (= 100 *109 cells/ L)
  3. Hemoglobin < 8.5 g/dL (= <85 g/L) (males) and <8g/dL (= <80 g/L) (women)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes. Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Experimental: Ixekizumab	Drug: Ixekizumab; Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes. Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.; Other Names: Taltz

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Residual insulin secretion	Change in residual insulin secretion measured by stimulated C-peptide two-hour area under the curve profile measured by Mixed Meal Tolerance Test (MMTT) between baseline and week 52.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Insulin dosage per kilo bodyweight for 24 hours	Change in mean Insulin dosage per kilo bodyweight for 24 hours from baseline to week 52.	12 months
Time with glucose levels in range (3.9-10 mmol/L)	Change in time with glucose levels in range (3.9-10 mmol/l) measured by CGM/FGM from baseline to week 52.	12 months
Time in hypoglycaemia (<3.9 mmol/L)	Change in time in hypoglycaemia (<3.9 mmol/L) measured by CGM/FGM from baseline to week 52.	12 months
HbA1c	Difference in HbA1c from baseline to week 52.	12 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time in hypoglycaemia (<3.0 mmol/L)	Change in time in hypoglycaemia (<3.0 mmol/L) measured by CGM/FGM from baseline to week 52.	12 months
Proinsulin/c-peptide ratio in serum as a measure of beta cell stress	Change in proinsulin/c-peptide ratio in serum as a measure of beta cell stress from baseline to week 52.	12 months
Time in target (3.9-8 mmol/L)	Change in time in target (3.9-8 mmol/L) measured by CGM/FGM from baseline to week 52.	12 months
Time in hyperglycaemia >10 mmol/L and ≥ 14 mmol/L	Change in time in hyperglycaemia >10 mmol/L and ≥ 14 mmol/L measured by CGM/FGM from baseline to week 52.	12 months
Glycaemic variability (mean amplitude of glycemic excursions (MAGE))	Change in glycaemic variability measured by mean amplitude of glycemic excursions (MAGE) by CGM/FGM from baseline to week 52.	12 months
Glycaemic variability (coefficient of variation (CV))	Change in glycaemic variability measured by coefficient of variation (CV) by CGM/FGM from baseline to week 52.	12 months
Glycaemic variability (standard deviation (SD))	Change in glycaemic variability measured by standard deviation (SD) by CGM/FGM from baseline to week 52.	12 months
Proportion of patients with peak residual insulin secretion	Change in proportion of patients with peak residual insulin secretion measured by MMTT: stimulated C-peptide >0.4 pmol/mL from baseline to week 52	12 months
Change in World Health Organization-5 (WHO-5) scores from baseline and week 52.	Score 0 to 100; higher value indicates better well-being	12 months
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores from baseline and week 52.	Score 0 to 36; higher value indicates better satisfaction and change in satisfaction (score -18 to 18; higher value indicates better change in satisfaction).	12 months
Change in Hypoglycaemia Fear Survey (Swe-HFS) scores from baseline and week 52.	Score 0 to 4; higher value indicates greater fear.	12 months
Change in Problem Areas in Diabetes Scale (PAID) scores from baseline and week 52.	Score 0 to 100; higher value indicates greater problems.	12 months
Change in International Physical Activity Questionnaire (IPAQ) scores from baseline and week 52.	Total Physical Activity Scores are calculated by Metabolic Energy Turnover (MET)-minutes/week score.	12 months

Collaborators and Investigators

• Sponsor: Göteborg University
• Collaborators: Gothia Forum - Center for Clinical Trial; Statistiska Konsultgruppen

Publications and helpful links

General Publications

• Seyed Ahmadi S, Korsgren O, Jansson PA, Lind M. Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes. BMJ Open. 2025 Nov 12;15(11):e103486. doi: 10.1136/bmjopen-2025-103486.

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2022
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: September 24, 2020
• First Submitted That Met QC Criteria: October 14, 2020
• First Posted (Actual): October 19, 2020

Study Record Updates

• Last Update Posted (Actual): April 27, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Type 1 diabetes; New-onset; MMTT; Ixekizumab
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 1; Dermatologic Agents; ixekizumab
• Other Study ID Numbers: IDIT001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No